1
|
Perna G, Pinto E, Spiti A, Torti T, Cucchi M, Caldirola D. Foundations for a Personalized Psycho-Oncology: The State of the Art. J Pers Med 2024; 14:892. [PMID: 39338146 PMCID: PMC11433554 DOI: 10.3390/jpm14090892] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/29/2024] [Revised: 08/09/2024] [Accepted: 08/21/2024] [Indexed: 09/30/2024] Open
Abstract
Personalized psycho-oncology represents a major challenge for the holistic care of cancer patients. It focuses on individualized psychotherapeutic and psychiatric interventions to address specific psychological needs. This narrative review summarizes the current literature on personalized psycho-oncology and highlights the prevalence and impact of psychiatric/psychological disorders in cancer patients. Personalized approaches, including tailored interventions and interdisciplinary collaboration, have been shown to be effective in improving mental health and overall quality of life. The integration of inflammatory biomarkers into treatment plans is a promising but challenging way to alleviate mental health problems. In addition, there is a need for specific diagnostic tools and treatment guidelines that take into account the specific psychological impact of different types of cancer. Future research should aim to refine these personalized strategies, improve diagnostic accuracy, and evaluate the cost-effectiveness of these interventions to improve both the psychological well-being and treatment outcomes of cancer patients.
Collapse
Affiliation(s)
- Giampaolo Perna
- Department of Biological Sciences, Humanitas University, 20089 Milan, Italy;
- IRCCS Humanitas Research Hospital, 20089 Milan, Italy; (A.S.); (M.C.)
| | - Eleonora Pinto
- Veneto Institute of Oncology IOV–IRCCS, 35128 Padua, Italy;
| | - Alessandro Spiti
- IRCCS Humanitas Research Hospital, 20089 Milan, Italy; (A.S.); (M.C.)
| | - Tatiana Torti
- ASIPSE School of Cognitive-Behavioral-Therapy, 20124 Milan, Italy;
| | - Michele Cucchi
- IRCCS Humanitas Research Hospital, 20089 Milan, Italy; (A.S.); (M.C.)
| | - Daniela Caldirola
- Department of Biological Sciences, Humanitas University, 20089 Milan, Italy;
| |
Collapse
|
2
|
Civilotti C, Lucchini D, Fogazzi G, Palmieri F, Benenati A, Buffoli A, Girardi V, Ruzzenenti N, Di Betta A, Donarelli E, Veglia F, Di Fini G, Gandino G. The role of integrated psychological support in breast cancer patients: a randomized monocentric prospective study evaluating the Fil-Rouge Integrated Psycho-Oncological Support (FRIPOS) program. Support Care Cancer 2023; 31:266. [PMID: 37058253 PMCID: PMC10104919 DOI: 10.1007/s00520-023-07732-4] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/16/2022] [Accepted: 04/04/2023] [Indexed: 04/15/2023]
Abstract
PURPOSE This study examined the effects of Fil-Rouge Integrated Psycho-Oncological Support (FRIPOS) in a group of women with breast cancer compared with a group receiving treatment as usual (TAU). METHODS The research design was a randomized, monocentric, prospective study with three time points of data collection: after the preoperative phase (T0), in the initial phase of treatments (T1), and 3 months after the start of treatments (T2). The FRIPOS group (N = 103) and the TAU group (N = 79) completed a sociodemographic questionnaire, the Symptom Checklist-90-R (SCL-90-R) at T0; the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ) C30 and EORTC QLQ-BR23 at T1; and SCL-90-R, EORTC QLQ-C30, and EORTC QLQ-BR23 at T2. RESULTS A series of independent and paired t tests showed that patients in the FRIPOS group performed better on all scales related to symptomatic manifestations and on some quality of life scales (fatigue, dyspnea, and sleep disturbances) at T2. In addition, a series of ten multiple regressions were performed to predict each SCL subscale at T2 from the SCL score at T0 and the EORTC QLQ-C30 scores at T2. In nine of ten regression models (all except somatization), both FRIPOS group membership and QoL subscale contributed significantly to prediction. CONCLUSIONS This study suggests that patients in the FRIPOS group have more benefits in emotional, psychological, and collateral symptoms than patients in the TAU group and that these improvements are due to integrated psycho-oncology care.
Collapse
Affiliation(s)
- Cristina Civilotti
- Department of Psychology, University of Turin, Turin, Italy
- Salesian University Institute (IUSTO), Turin, Italy
| | - Diana Lucchini
- Breast Psycho-Oncology, EUSOMA-Certified Breast Unit, Istituto Clinico Sant'Anna, Via del Franzone 31, 25127, Brescia, Italy
- Associazione Priamo, Via della Lama, 61, 25133, Brescia, Italy
| | - Gianluca Fogazzi
- Breast Medical Oncology, EUSOMA-Certified Breast Unit, Istituto Clinico Sant'Anna, Via del Franzone 31, 25127, Brescia, Italy
| | - Fabrizio Palmieri
- Breast Surgery, EUSOMA-Certified Breast Unit, Istituto Clinico Sant'Anna, Via del Franzone 31, 25127, Brescia, Italy
| | - Alice Benenati
- Breast Surgery, EUSOMA-Certified Breast Unit, Istituto Clinico Sant'Anna, Via del Franzone 31, 25127, Brescia, Italy
- Radiation Oncology, EUSOMA-Certified Breast Unit, Istituto Clinico Sant'Anna, Via del Franzone 31, 25127, Brescia, Italy
| | - Alberto Buffoli
- Radiation Oncology, EUSOMA-Certified Breast Unit, Istituto Clinico Sant'Anna, Via del Franzone 31, 25127, Brescia, Italy
| | - Veronica Girardi
- Breast Radiology, EUSOMA-Certified Breast Unit, Istituto Clinico Sant'Anna, Via del Franzone 31, 25127, Brescia, Italy
| | - Nella Ruzzenenti
- Breast Pathology, EUSOMA-Certified Breast Unit, Istituto Clinico Sant'Anna, Via del Franzone 31, 25127, Brescia, Italy
| | | | | | - Fabio Veglia
- Department of Psychology, University of Turin, Turin, Italy
| | - Giulia Di Fini
- Department of Psychology, University of Turin, Turin, Italy.
| | | |
Collapse
|
3
|
Post KE, Heuer LB, Kamal AH, Kumar P, Elyze M, Griffith S, Han J, Friedman F, Jackson A, Trotter C, Plotke R, Vyas C, Jackson V, Rabideau DJ, Greer JA, Temel JS. Study protocol for a randomised trial evaluating the non-inferiority of stepped palliative care versus early integrated palliative care for patients with advanced lung cancer. BMJ Open 2022; 12:e057591. [PMID: 35144954 PMCID: PMC8845218 DOI: 10.1136/bmjopen-2021-057591] [Citation(s) in RCA: 6] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/25/2022] Open
Abstract
INTRODUCTION Integrating palliative care (PC) early in the illness course for patients with serious cancers improves their outcomes and is recommended by national organisations such as the American Society of Clinical Oncology. However, monthly visits with PC clinicians from the time of diagnosis can be challenging to implement due to the lack of specialty-trained PC clinicians and resources. Therefore, we developed a stepped care model to triage PC service based on patients' needs. METHODS AND ANALYSIS We are conducting a non-blinded, randomised trial to evaluate the non-inferiority of a stepped PC model compared with an early integrated PC model for improving patients' quality of life (QOL) at 24 weeks (primary outcome). Patients assigned to early integrated PC meet with PC every 4 weeks throughout their illness. Patients assigned to stepped PC have PC visits only at clinically significant points in their illness (eg, cancer progression) unless their QOL decreases, at which time they are 'stepped up' and meet with PC every 4 weeks throughout the remainder of their illness. Secondary aims include assessing whether stepped PC is non-inferior to early integrated PC regarding patient-clinician communication about end of life care and length of stay on hospice as well as comparing resource utilisation. Patients are recruited from the Massachusetts General Hospital Cancer Center, Boston, Massachusetts; Duke Cancer Center, Durham, North Carolina and University of Pennsylvania Abramson Cancer Center, Philadelphia, Pennsylvania. The target sample size is 510 patients. ETHICS AND DISSEMINATION The study is funded by the National Cancer Institute, approved by the Dana-Farber/Harvard Cancer Center Institutional Review Board and will be reported in accordance with the Consolidated Standards of Reporting Trials statement. We will disseminate results through professional society meetings, peer-reviewed publications and presentations to patient organisations. TRIAL REGISTRATION NUMBER NCT03337399.
Collapse
Affiliation(s)
- Kathryn E Post
- Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA
| | - Lauren B Heuer
- Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA
| | - Arif H Kamal
- Medicine, Duke University School of Medicine, Durham, North Carolina, USA
| | - Pallavi Kumar
- Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA
| | - Madeleine Elyze
- Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA
| | - Sarah Griffith
- Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA
| | - Jacqueline Han
- Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA
| | - Fred Friedman
- Medicine, Duke University School of Medicine, Durham, North Carolina, USA
| | - Ashley Jackson
- Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA
| | - Chardria Trotter
- Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA
| | - Rachel Plotke
- Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA
| | - Charu Vyas
- Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA
| | - Vicki Jackson
- Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA
| | - Dustin J Rabideau
- Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA
| | - Joseph A Greer
- Psychiatry, Massachusetts General Hospital, Boston, Massachusetts, USA
| | - Jennifer S Temel
- Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA
| |
Collapse
|
4
|
Simon M, Wawer Matos PA, Meinel J, Rokohl AC, Heindl LM. Klinisches Vorgehen bei periokulären Lymphomen. Ophthalmologe 2022; 119:686-691. [DOI: 10.1007/s00347-021-01568-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 12/22/2021] [Indexed: 10/19/2022]
|
5
|
Frasquilho D, Matias R, Grácio J, Sousa B, Luís-Ferreira F, Leal J, Cardoso F, Oliveira-Maia AJ. Protocol for the Implementation and Assessment of "MoodUP": A Stepped Care Model Assisted by a Digital Platform to Accelerate Access to Mental Health Care for Cancer Patients Amid the COVID-19 Pandemic. INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH 2021; 18:ijerph18094629. [PMID: 33925412 PMCID: PMC8123812 DOI: 10.3390/ijerph18094629] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 03/28/2021] [Revised: 04/21/2021] [Accepted: 04/23/2021] [Indexed: 12/18/2022]
Abstract
The COVID-19 pandemic has important consequences for the mental health of populations. Patients with cancer, already at risk for poor mental health outcomes, are not expected to be spared from these consequences, prompting the need for health services to improve responsiveness. This article presents the research protocol for an implementation study designed to describe the uptake of a well-studied and recognized system for the treatment of depression and anxiety (Stepped-care) during the specific context of a Pandemic in an oncological site. The system set-up will be assisted by a digital platform (MoodUP), where patients undergoing cancer treatment will be screened for anxiety and depressive symptoms, triaged by severity level and algorithm-matched to recommended interventions. Patients undergoing cancer treatment at a cancer clinic in Portugal will be invited to subscribe to the MoodUP platform where they will complete a self-reported questionnaire (Hospital Anxiety and Depression Scale) to screen their anxiety and depressive symptoms. Data will be instantly collected, and an algorithm will activate severity-matched intervention suggestions, through a case manager that will coordinate care. The specific objectives of this study will be to describe the implementation and acceptability of the care system by patients and staff, the barriers to and facilitators of implementation, the proportion of patients accessing the system and their pathways through the various stepped-care interventions, and patient perceptions regarding the feasibility and appropriateness of the eHealth platform. Moreover, exploratory analyses will be conducted to describe patterns of anxiety and depression symptoms variation across all patients, as well as within sociodemographically, clinically and contextually characterized subgroups, to characterize their care needs and access, as well as to explore for whom the MoodUP care system may be more appropriate. This study is expected to improve processes for collaborative mental healthcare in oncology and accelerate the digitalization of services, towards the improvement of mental healthcare access, and management of high-risk patients, during the COVID-19 pandemic.
Collapse
Affiliation(s)
- Diana Frasquilho
- Champalimaud Clinical Centre, Breast Unit, Champalimaud Centre for the Unknown, Champalimaud Foundation, 1400-038 Lisboa, Portugal; (B.S.); (F.C.)
- Champalimaud Research, Champalimaud Centre for the Unknown, Champalimaud Foundation, 1400-038 Lisboa, Portugal
- Correspondence: ; Tel.: +351-210-480-006
| | - Ricardo Matias
- Champalimaud Research and Clinical Centre, Neuropsychiatry Unit, Champalimaud Centre for the Unknown, Champalimaud Foundation, 1400-038 Lisboa, Portugal; (R.M.); (J.G.); (A.J.O.-M.)
- Human Movement Analysis Lab, Escola Superior Saúde—Instituto Politécnico de Setuúbal, 2914-503 Setúbal, Portugal
| | - Jaime Grácio
- Champalimaud Research and Clinical Centre, Neuropsychiatry Unit, Champalimaud Centre for the Unknown, Champalimaud Foundation, 1400-038 Lisboa, Portugal; (R.M.); (J.G.); (A.J.O.-M.)
- NOVA Medical School, NMS, Universidade Nova de Lisboa, 1169-056 Lisboa, Portugal
| | - Berta Sousa
- Champalimaud Clinical Centre, Breast Unit, Champalimaud Centre for the Unknown, Champalimaud Foundation, 1400-038 Lisboa, Portugal; (B.S.); (F.C.)
| | - Fernando Luís-Ferreira
- Electrical Engineering Department, School of Science and Technology, CTS, FCT NOVA, Universidade Nova de Lisboa, 2829-516 Caparica, Portugal; (F.L.-F.); (J.L.)
| | - João Leal
- Electrical Engineering Department, School of Science and Technology, CTS, FCT NOVA, Universidade Nova de Lisboa, 2829-516 Caparica, Portugal; (F.L.-F.); (J.L.)
| | - Fátima Cardoso
- Champalimaud Clinical Centre, Breast Unit, Champalimaud Centre for the Unknown, Champalimaud Foundation, 1400-038 Lisboa, Portugal; (B.S.); (F.C.)
| | - Albino J. Oliveira-Maia
- Champalimaud Research and Clinical Centre, Neuropsychiatry Unit, Champalimaud Centre for the Unknown, Champalimaud Foundation, 1400-038 Lisboa, Portugal; (R.M.); (J.G.); (A.J.O.-M.)
- NOVA Medical School, NMS, Universidade Nova de Lisboa, 1169-056 Lisboa, Portugal
| |
Collapse
|
6
|
Virtue SM, Duffy N, Howrey HL. Re-referrals to a Psychosocial oncology department: A data-informed approach to Practice. Psychooncology 2021; 30:421-425. [PMID: 33450109 DOI: 10.1002/pon.5626] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/20/2020] [Accepted: 01/06/2021] [Indexed: 11/09/2022]
Affiliation(s)
- Shannon M Virtue
- Helen F. Graham Cancer Center & Research Institute, Christiana Care Health System, Newark, Delaware, USA
| | - Nicole Duffy
- Helen F. Graham Cancer Center & Research Institute, Christiana Care Health System, Newark, Delaware, USA
| | - Hillary L Howrey
- Helen F. Graham Cancer Center & Research Institute, Christiana Care Health System, Newark, Delaware, USA
| |
Collapse
|
7
|
[Ocular lymphoma : Precise diagnostics and classification as key for successful personalized treatment]. Ophthalmologe 2020; 117:499-507. [PMID: 31811368 DOI: 10.1007/s00347-019-01020-5] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Abstract
BACKGROUND Personalized medicine is nowadays the standard of care for patients with oncological diseases. A prime example is the lymphoma, which has substantial points of contact with ophthalmological care due to the intraocular and periocular involvement. OBJECTIVE This article provides a description of the current personalized diagnostics and treatment of ocular lymphomas. METHODS This article constructs a relationship between the current knowledge in the literature, guidelines and recommendations and the clinical experience with ocular lymphomas. It explains in particular the molecular and also individual personalized treatment concepts. RESULTS The primary suspicion of lymphatic or other ocular oncological diseases is raised by an ophthalmologist based on clinical symptoms. The exact diagnostic procedure is carried out with molecular biological techniques, such as immunohistology and polymerase chain reaction analyses. A staging of the mass is indispensable and the stage classification according to the Ann Arbor criteria for a correct assignment of the lymphoma is of clinical importance. Based on these precise diagnostics an individualized choice of treatment and subsequent personalized follow-up care are carried out. During the complete process from the diagnostic procedure to treatment and aftercare, psycho-oncological support should be offered to the patient. CONCLUSION Personalized medicine is already actively performed in the care of ocular lymphomas. The patient is in the forefront and plays a decisive role. By considering the special features of the tumor and patient parameters, the life expectation and relapse-free interval as well as quality of life have been improved for many types of lymphoma. It must be assumed that these advantages also apply to ophthalmology.
Collapse
|
8
|
Structured multi-disciplinary psychosocial care for cancer patients and the perceived quality of care from the patient perspective: a cluster-randomized trial. J Cancer Res Clin Oncol 2019; 145:2845-2854. [DOI: 10.1007/s00432-019-03018-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/26/2019] [Accepted: 09/03/2019] [Indexed: 10/26/2022]
|
9
|
Schouten B, Avau B, Bekkering G(TE, Vankrunkelsven P, Mebis J, Hellings J, Van Hecke A. Systematic screening and assessment of psychosocial well-being and care needs of people with cancer. Cochrane Database Syst Rev 2019; 3:CD012387. [PMID: 30909317 PMCID: PMC6433560 DOI: 10.1002/14651858.cd012387.pub2] [Citation(s) in RCA: 22] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
Abstract
BACKGROUND Receiving a diagnosis of cancer and the subsequent related treatments can have a significant impact on an individual's physical and psychosocial well-being. To ensure that cancer care addresses all aspects of well-being, systematic screening for distress and supportive care needs is recommended. Appropriate screening could help support the integration of psychosocial approaches in daily routines in order to achieve holistic cancer care and ensure that the specific care needs of people with cancer are met and that the organisation of such care is optimised. OBJECTIVES To examine the effectiveness and safety of screening of psychosocial well-being and care needs of people with cancer. To explore the intervention characteristics that contribute to the effectiveness of these screening interventions. SEARCH METHODS We searched five electronic databases in January 2018: the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, Embase, PsycINFO, and CINAHL. We also searched five trial registers and screened the contents of relevant journals, citations, and references to find published and unpublished trials. SELECTION CRITERIA We included randomised controlled trials (RCTs) and non-randomised controlled trials (NRCTs) that studied the effect of screening interventions addressing the psychosocial well-being and care needs of people with cancer compared to usual care. These screening interventions could involve self-reporting of people with a patient-reported outcome measures (PROMs) or a semi-structured interview with a screening interventionist, and comprise a solitary screening intervention or screening with guided actions. We excluded studies that evaluated screening integrated as an element in more complex interventions (e.g. therapy, coaching, full care pathways, or care programmes). DATA COLLECTION AND ANALYSIS Two review authors independently extracted the data and assessed methodological quality for each included study using the Cochrane tool for RCTs and the Risk Of Bias In Non-randomised Studies - of Interventions (ROBINS-I) tool for NRCTs. Due to the high level of heterogeneity in the included studies, only three were included in meta-analysis. Results of the remaining 23 studies were analysed narratively. MAIN RESULTS We included 26 studies (18 RCTs and 8 NRCTs) with sample sizes of 41 to 1012 participants, involving a total of 7654 adults with cancer. Two studies included only men or women; all other studies included both sexes. For most studies people with breast, lung, head and neck, colorectal, prostate cancer, or several of these diagnoses were included; some studies included people with a broader range of cancer diagnosis. Ten studies focused on a solitary screening intervention, while the remaining 16 studies evaluated a screening intervention combined with guided actions. A broad range of intervention instruments was used, and were described by study authors as a screening of health-related quality of life (HRQoL), distress screening, needs assessment, or assessment of biopsychosocial symptoms or overall well-being. In 13 studies, the screening was a self-reported questionnaire, while in the remaining 13 studies an interventionist conducted the screening by interview or paper-pencil assessment. The interventional screenings in the studies were applied 1 to 12 times, without follow-up or from 4 weeks to 18 months after the first interventional screening. We assessed risk of bias as high for eight RCTs, low for five RCTs, and unclear for the five remaining RCTs. There were further concerns about the NRCTs (1 = critical risk study; 6 = serious risk studies; 1 = risk unclear).Due to considerable heterogeneity in several intervention and study characteristics, we have reported the results narratively for the majority of the evidence.In the narrative synthesis of all included studies, we found very low-certainty evidence for the effect of screening on HRQoL (20 studies). Of these studies, eight found beneficial effects of screening for several subdomains of HRQoL, and 10 found no effects of screening. One study found adverse effects, and the last study did not report quantitative results. We found very low-certainty evidence for the effect of screening on distress (16 studies). Of these studies, two found beneficial effects of screening, and 14 found no effects of screening. We judged the overall certainty of the evidence for the effect of screening on HRQoL to be very low. We found very low-certainty evidence for the effect of screening on care needs (seven studies). Of these studies, three found beneficial effects of screening for several subdomains of care needs, and two found no effects of screening. One study found adverse effects, and the last study did not report quantitative results. We judged the overall level of evidence for the effect of screening on HRQoL to be very low. None of the studies specifically evaluated or reported adverse effects of screening. However, three studies reported unfavourable effects of screening, including lower QoL, more unmet needs, and lower satisfaction.Three studies could be included in a meta-analysis. The meta-analysis revealed no beneficial effect of the screening intervention on people with cancer HRQoL (mean difference (MD) 1.65, 95% confidence interval (CI) -4.83 to 8.12, 2 RCTs, 6 months follow-up); distress (MD 0.0, 95% CI -0.36 to 0.36, 1 RCT, 3 months follow-up); or care needs (MD 2.32, 95% CI -7.49 to 12.14, 2 RCTs, 3 months follow-up). However, these studies all evaluated one specific screening intervention (CONNECT) in people with colorectal cancer.In the studies where some effects could be identified, no recurring relationships were found between intervention characteristics and the effectiveness of screening interventions. AUTHORS' CONCLUSIONS We found low-certainty evidence that does not support the effectiveness of screening of psychosocial well-being and care needs in people with cancer. Studies were heterogeneous in population, intervention, and outcome assessment.The results of this review suggest a need for more uniformity in outcomes and reporting; for the use of intervention description guidelines; for further improvement of methodological certainty in studies and for combining subjective patient-reported outcomes with objective outcomes.
Collapse
Affiliation(s)
- Bojoura Schouten
- Hasselt UniversityResearch Group Health Care, Faculty of Medicine and Life SciencesHasseltLimburgBelgium3500
| | - Bert Avau
- Belgian Red CrossCentre for Evidence‐Based PracticeMotstraat 42MechelenBelgium2800
- Belgian Centre for Evidence‐Based Medicine ‐ Cochrane BelgiumKapucijnenvoer 33, blok JLeuvenBelgium3000
| | - Geertruida (Trudy) E Bekkering
- Belgian Centre for Evidence‐Based Medicine ‐ Cochrane BelgiumKapucijnenvoer 33, blok JLeuvenBelgium3000
- KU LeuvenDepartment of Public Health and Primary Care ‐ Faculty of MedicineKapucijnenvoer 33 Blok J Bus 7001LeuvenBelgium3000
| | - Patrick Vankrunkelsven
- Belgian Centre for Evidence‐Based Medicine ‐ Cochrane BelgiumKapucijnenvoer 33, blok JLeuvenBelgium3000
- KU LeuvenDepartment of Public Health and Primary Care ‐ Faculty of MedicineKapucijnenvoer 33 Blok J Bus 7001LeuvenBelgium3000
| | - Jeroen Mebis
- Jessa HospitalDepartment of Medical OncologyHasseltBelgium
- Hasselt UniversityResearch Group Immunology and BiochemistryFaculty of Medicine and Life SciencesHasseltBelgium
| | - Johan Hellings
- Hasselt UniversityResearch Group Health Care, Faculty of Medicine and Life SciencesHasseltLimburgBelgium3500
- AZ DeltaRode‐Kruisstraat 20RoeselareBelgium
| | - Ann Van Hecke
- Ghent UniversityUniversity Centre for Nursing and Midwifery, Department of Public HealthDe Pintelaan 185GhentBelgium9000
| | | |
Collapse
|
10
|
Abstract
The treatment options for basal cell carcinoma (BCC) have recently been augmented with the introduction of novel chemotherapeutic drugs. New S2 guidelines on the disease have also been published. The aim of this article is to present a comprehensive state of the art description of the features of ocular BCC and an overview of the various therapeutic options. Particular emphasis is placed on the clinical signs, the diagnostic tools to identify periocular BCC and interpretation of the different histopathological subtypes. Tumor staging, TNM classification, interdisciplinary tumor conference reviews as well as psycho-oncological services play an important role in patients with pronounced periocular BCC. Surgical removal with a histological R0 resection is an important component of therapy options in this disease and includes the microsurgical excision into healthy tissue and the subsequent covering of the defect. A special focus of this article is the treatment of locally extensive and metastasized BCC.
Collapse
|
11
|
Singer S, Danker H, Roick J, Einenkel J, Briest S, Spieker H, Dietz A, Hoffmann I, Papsdorf K, Meixensberger J, Mössner J, Schiefke F, Dietel A, Wirtz H, Niederwieser D, Berg T, Kersting A. Effects of stepped psychooncological care on referral to psychosocial services and emotional well-being in cancer patients: A cluster-randomized phase III trial. Psychooncology 2017; 26:1675-1683. [DOI: 10.1002/pon.4492] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/05/2016] [Revised: 05/11/2017] [Accepted: 06/27/2017] [Indexed: 12/17/2022]
Affiliation(s)
- Susanne Singer
- Institute of Medical Biostatistics, Epidemiology, and Informatics (IMBEI); University Medical Centre Mainz; Mainz Germany
- University Cancer Centre; University Medical Centre Mainz; Mainz Germany
| | - Helge Danker
- Department of Medical Psychology and Medical Sociology; University Medical Centre Leipzig; Leipzig Germany
- Department of Psychosomatic Medicine and Psychotherapy; University Medical Centre Leipzig; Leipzig Germany
| | - Julia Roick
- Department of Medical Sociology; University of Halle; Halle Germany
| | - Jens Einenkel
- Department of Obstetrics and Gynaecology; University Medical Centre Leipzig; Leipzig Germany
| | - Susanne Briest
- Department of Obstetrics and Gynaecology; University Medical Centre Leipzig; Leipzig Germany
| | - Henning Spieker
- Department of Surgery; University Medical Centre Leipzig; Leipzig Germany
| | - Andreas Dietz
- Department of Otolaryngology; University Medical Centre Leipzig; Leipzig Germany
| | - Isabell Hoffmann
- Institute of Medical Biostatistics, Epidemiology, and Informatics (IMBEI); University Medical Centre Mainz; Mainz Germany
| | - Kirsten Papsdorf
- Department of Radiation-Oncology; University Medical Centre Leipzig; Leipzig Germany
| | | | - Joachim Mössner
- Department of Gastroenterology; University Medical Centre Leipzig; Leipzig Germany
| | - Franziska Schiefke
- Department of Maxillofacial Surgery; University Medical Centre Leipzig; Leipzig Germany
| | - Anja Dietel
- Department of Urology; University Medical Centre Leipzig; Leipzig Germany
| | - Hubert Wirtz
- Department of Pneumology; University Medical Centre Leipzig; Leipzig Germany
| | - Dietger Niederwieser
- Department of Medical Oncology; University Medical Centre Leipzig; Leipzig Germany
| | - Thomas Berg
- Division of Hepatology; University Medical Centre Leipzig; Leipzig Germany
| | - Anette Kersting
- Department of Psychosomatic Medicine and Psychotherapy; University Medical Centre Leipzig; Leipzig Germany
| |
Collapse
|
12
|
Roick J, Danker H, Kersting A, Briest S, Dietrich A, Dietz A, Einenkel J, Papsdorf K, Lordick F, Meixensberger J, Mössner J, Niederwieser D, Prietzel T, Schiefke F, Stolzenburg JU, Wirtz H, Singer S. Factors associated with non-participation and dropout among cancer patients in a cluster-randomised controlled trial. Eur J Cancer Care (Engl) 2017; 27. [PMID: 28134477 DOI: 10.1111/ecc.12645] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 12/05/2016] [Indexed: 12/01/2022]
Abstract
We investigated the impact of demographic and disease related factors on non-participation and dropout in a cluster-randomised behavioural trial in cancer patients with measurements taken between hospitalisation and 6 months thereafter. The percentages of non-participation and dropout were documented at each time point. Factors considered to be potentially related with non-participation and dropout were as follows: age, sex, marital status, education, income, employment status, tumour site and stage of disease. Of 1,338 eligible patients, 24% declined participation at baseline. Non-participation was higher in older patients (Odds Ratio [OR] 2.1, CI: 0.6-0.9) and those with advanced disease (OR 2.0, CI: 0.1-1.3). Dropout by 6 months was 25%. Dropout was more frequent with increased age (OR 2.8, CI: 0.8-1.2), advanced disease (OR 3.0, CI: 1.0-1.2), being married (OR 2.4, CI 0.7-1.1) and less frequent with university education (OR 0.4, CI -1.3 to -0.8) and middle income (OR 0.4, CI -0.9 to -0.7). When planning clinical trials, it is important to be aware of patient groups at high risk of non-participation or dropout, for example older patients or those with advanced disease. Trial designs should consider their special needs to increase their rate of participation.
Collapse
Affiliation(s)
- J Roick
- Department of Psychosomatic Medicine and Psychotherapy, University Medical Center Leipzig, Leipzig, Germany
| | - H Danker
- Department of Psychosomatic Medicine and Psychotherapy, University Medical Center Leipzig, Leipzig, Germany
| | - A Kersting
- Department of Psychosomatic Medicine and Psychotherapy, University Medical Center Leipzig, Leipzig, Germany
| | - S Briest
- Department of Obstetrics and Gynecology, University Medical Center Leipzig, Leipzig, Germany
| | - A Dietrich
- Department of Visceral-, Transplantation-, Thoracic-, and Vascular Surgery, University Medical Center Leipzig, Leipzig, Germany
| | - A Dietz
- Department of Otolaryngology, University Medical Center Leipzig, Leipzig, Germany
| | - J Einenkel
- Department of Obstetrics and Gynecology, University Medical Center Leipzig, Leipzig, Germany
| | - K Papsdorf
- Department of Radiation-Oncology, University Medical Center Leipzig, Leipzig, Germany
| | - F Lordick
- University Cancer Center, University Medical Center Leipzig, Leipzig, Germany
| | - J Meixensberger
- Department of Neurosurgery, University Medical Center Leipzig, Leipzig, Germany
| | - J Mössner
- Department of Gastroenterology, University Medical Center Leipzig, Leipzig, Germany
| | - D Niederwieser
- Department of Hematology and Oncology, University Medical Center Leipzig, Leipzig, Germany
| | - T Prietzel
- Department of Orthopedics and Accident Surgery, Helios Clinic Blankenhain, Blankenhain, Germany
| | - F Schiefke
- Department of Maxillofacial Surgery, University Medical Center Leipzig, Leipzig, Germany
| | - J-U Stolzenburg
- Department of Urology, University Medical Center Leipzig, Leipzig, Germany
| | - H Wirtz
- Department of Pneumology, University Medical Center Leipzig, Leipzig, Germany
| | - S Singer
- Institute of Medical Biostatistics, Epidemiology and Informatics (IMBEI), University Medical Centre of Johannes Gutenberg University Mainz, Mainz, Germany
| |
Collapse
|
13
|
Schouten B, Bekkering GE, Vankrunkelsven P, Mebis J, Van Hoof E, Hellings J, Van Hecke A. Systematic screening and assessment of psychosocial well-being and care needs of people with cancer. THE COCHRANE DATABASE OF SYSTEMATIC REVIEWS 2016. [DOI: 10.1002/14651858.cd012387] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Affiliation(s)
- Bojoura Schouten
- Hasselt University; Research Group Health Care, Faculty of Medicine and Life Sciences; Hasselt Limburg Belgium 3500
| | - Geertruida E Bekkering
- Belgian Centre for Evidence-Based Medicine - Cochrane Belgium; Kapucijnenvoer 33 Blok J Bus 7001 Leuven Belgium 3000
- KU Leuven; Department of Public Health and Primary Care - Faculty of Medicine; Kapucijnenvoer 33 Blok J Bus 7001 Leuven Belgium 3000
| | - Patrick Vankrunkelsven
- Belgian Centre for Evidence-Based Medicine - Cochrane Belgium; Kapucijnenvoer 33 Blok J Bus 7001 Leuven Belgium 3000
- KU Leuven; Department of Public Health and Primary Care - Faculty of Medicine; Kapucijnenvoer 33 Blok J Bus 7001 Leuven Belgium 3000
| | - Jeroen Mebis
- Jessa Hospital; Department of Medical Oncology; Hasselt Belgium
- Hasselt University; Research Group Immunology and Biochemistry; Faculty of Medicine and Life Sciences Hasselt Belgium
| | - Elke Van Hoof
- Jessa Hospital; Department of Medical Oncology; Hasselt Belgium
| | - Johan Hellings
- Hasselt University; Research Group Health Care, Faculty of Medicine and Life Sciences; Hasselt Limburg Belgium 3500
- Free University of Brussels; Department of Experimental and Applied Psychology, Faculty of Psychological and Educational Sciences; Brussels Belgium
| | - Ann Van Hecke
- Ghent University; University Centre for Nursing and Midwifery, Department of Public Health; De Pintelaan 185 Ghent Belgium 9000
| |
Collapse
|
14
|
Abstract
BACKGROUND Lymphomas of the ocular adnexa are heterogeneous and demonstrate a wide range of clinical, histological, immunohistochemical and molecular genetic characteristics. AIM The aim of this article is to give an overview of the interdisciplinary diagnostics and individually adapted lymphoma subtype-based therapy. DIAGNOSTICS Depending on the lymphoma localisation, i.e. whether in the eyelid, the conjunctiva or in the orbit, a photograph or a radiological scan is required to record the tumor extent. Visual function is more likely to be impacted when the lymphoma arises in the posterior orbit, close to the optic nerve and imaging diagnostics are therefore necessary. Histological investigations are essential for confirming the lymphoma diagnosis and give information about the particular subtype, which in turn will determine subsequent patient management, Clinical staging investigations for determining the systemic extent of the lymphoma manifestation (e.g. imaging, blood analyses as well as bone marrow biopsy) are mandatory. THERAPY External beam radiation, local and systemic chemotherapy or in some cases antibiotics are treatment options after surgical excision in isolated ocular adnexal lymphoma. The TNM classification of the American Joint Committee on Cancer or the Ann Arbor staging system, as well as the guidelines of the German Society of Hematology and Medical Oncology are all tools to aid the choice of the appropriate individually adapted therapy for systemic disease, which includes psycho-oncological care.
Collapse
|
15
|
Psyche at the end of life: Psychiatric symptoms are prevalent in patients admitted to a palliative care unit. Palliat Support Care 2015; 14:250-8. [PMID: 26447347 DOI: 10.1017/s1478951515000899] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Abstract
OBJECTIVE Our aim was to evaluate the frequency and treatment of psychiatric symptoms in patients at palliative care units (PCUs). METHOD Patients admitted to one of five participating PCUs in Austria were included. The short version of the Patient Health Questionnaire (PHQ-D) was used to evaluate their mental health status. Pain intensity was rated on a numeric rating scale (NRS) from 0 to 10 by patients and physicians. Patients with a previously diagnosed psychiatric disorder were compared to those without or with newly diagnosed psychiatric symptoms, based on PHQ-D results. Pain and psychopharmacological medication were assessed. Opioid doses were converted into oral morphine equivalents (OMEs). RESULTS Some 68 patients were included. Previously undetected psychiatric symptoms were identified in 38% (26 of 68), preexisting psychiatric comorbidities were evident in 25% (17), and no psychiatric symptoms were observed in 37% (25). Patients with a preexisting psychiatric comorbidity received antidepressants and benzodiazepines significantly more often than patients without or with previously undetected psychiatric symptoms (p < 0.001). Patient and physician median NRS ratings of pain intensity correlated significantly (p = 0.001). Median NRS rating showed no significant difference between patients with preexisting, previously undetected, or without psychiatric symptoms. OMEs did not differ significantly between preexisting, without, or previously undetected psychiatric symptoms. Patients with undetected and preexisting psychiatric comorbidities had a greater impairment in their activities of daily living than patients without psychiatric symptoms (p = 0.003). SIGNIFICANCE OF RESULTS Undetected psychiatric comorbidities are common in patients receiving palliative care. Screening for psychiatric symptoms should be integrated into standard palliative care to optimize treatment and reduce the psychosocial burden of the disease.
Collapse
|